key: cord-0808038-i5h0gm3u
authors: Murison, K.; Grima, A.; Simmons, A.; Tuite, A.; Fisman, D.
title: Severity of SARS-CoV-2 Infection in Pregnancy in Ontario: A Matched Cohort Analysis
date: 2022-03-07
journal: nan
DOI: 10.1101/2022.03.04.22271915
sha: 78036bb0fbd0b7d4aaf94fe2520308fcf078b345
doc_id: 808038
cord_uid: i5h0gm3u

Background: Pregnancy represents a physiological state associated with increased vulnerability to severe outcomes from infectious diseases, both for the pregnant person and developing infant. The SARS-CoV-2 pandemic may have important health consequences for pregnant individuals, who may also be more reluctant than non-pregnant people to accept vaccination. We sought to estimate the degree to which increased severity of SARS-CoV-2 outcomes can be attributed to pregnancy. Methods: Our study made use of a population-based SARS-CoV-2 case file from Ontario, Canada. Due to both varying propensity to receive vaccination, and changes in dominant circulating viral strains over time, a time-matched cohort study was performed to evaluate the relative risk of severe illness in pregnant women with SARS-CoV-2 compared to other SARS-CoV-2 infected women of childbearing age (10 to 49 years old). Risk of severe SARS-CoV-2 outcomes (hospitalization or intensive care unit (ICU) admission) was evaluated in pregnant women and time-matched non-pregnant controls using multivariable conditional logistic regression. Results: Compared to the rest of the population, non-pregnant women of childbearing age had an elevated risk of infection (standardized morbidity ratio (SMR) 1.28), while risk of infection was reduced among pregnant women (SMR 0.43). After adjustment for age, comorbidity, healthcare worker status, vaccination, and infecting viral variant, pregnant women had a markedly elevated risk of hospitalization (adjusted OR 4.96, 95% CI 3.86 to 6.37) and ICU admission (adjusted OR 6.58, 95% CI 3.29 to 13.18). The relative increase in hospitalization risk associated with pregnancy was greater in women without comorbidities than in those with comorbidities (P for heterogeneity 0.004). Interpretation: A time-matched cohort study suggests that while pregnant women may be at a decreased risk of infection relative to the rest of the population, their risk of severe illness is markedly elevated if infection occurs. Given the safety of SARS-CoV-2 vaccines in pregnancy, risk-benefit calculus strongly favours SARS-CoV-2 vaccination in pregnant women.

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Introduction 54 55

CoV-2 attributable mortality (17) . A multi-province Canadian surveillance group has reported 78 elevated risk of hospitalization and critical illness associated with SARS-CoV-2 in pregnant 79 individuals in Canada, but this report was published in early June 2021, just as the Delta variant 80 of concern (VOC) was emerging, and relatively early in the Canadian SARS-CoV-2 vaccination 81 effort (18, 19) . Furthermore, this report was largely descriptive, and did not adjust for 82 confounding by VOC, vaccination, age, underlying comorbidity, or healthcare worker status. 83

The Canadian province of Ontario represents a large (population 14.6 million) and 84 diverse jurisdiction, with high levels of SARS-CoV-2 vaccine coverage (approximately 80% as 85 of December 2021) (20, 21) . Ontario has weathered multiple pandemic waves due to the original 86 circulating variant of SARS-CoV-2, and latterly waves caused by the Alpha (spring 2021) and 87

Delta (summer and autumn, 2021) VOC (22) , with the Omicron VOC displacing Delta in 88

December 2021 (23) . 89

The province's rich data sources provide an opportunity for evaluation of the impact of 90 SARS-CoV-2 in pregnant women, relative to other women of childbearing age, and with 91 adjustment for important confounders. Our principal objective was to evaluate the relative 92 morbidity associated with SARS-CoV-2 infection in pregnancy in Ontario. Secondary objectives 93 were to evaluate the impact of infecting VOC and vaccination status on SARS-CoV-2 outcomes. 94 95 96 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Contact Management (CCM) database as described elsewhere (24, 25) ; we included only cases 105 with a unique "pseudo-health card number", which permitted linkage with the provincial 106 vaccination database. Control selection was limited to women of reproductive age. As data 107 were available by 10-year age bands, we considered "reproductive age" to encompass 108 individuals aged 10 to 49. Data on comorbidities, healthcare worker status, and infecting variant 109 were also available in CCM. Comorbidities included neurologic disorders, asthma, renal 110 conditions, blood disorders, cancer, cardiovascular conditions, liver conditions, and obesity. We 111 included the time period between January 1, 2020 and January 4, 2022 in the analysis. 112

Population denominators for the population overall and for women aged 10-49 in 113

Ontario, were obtained from Statistics Canada (20) . We estimated person-time at risk of SARS-114

CoV-2 infection among pregnant individuals based on reports of 107,855 live births and 482 115 stillbirths among women of childbearing age in Ontario between January 1 and October 31, 2021 116 (26) . Person time at risk was adjusted based on an assumed duration of pregnancy of 40 weeks. 117

To estimate person-time at risk of SARS-CoV-2 infection for non-pregnant women of 118 childbearing age, we subtracted estimated annual person time at risk among pregnant individuals 119 from the population of women of childbearing age. The person-time at risk among those not 120 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 7, 2022. ; https://doi.org/10.1101/2022.03.04.22271915 doi: medRxiv preprint classified as women of childbearing age was estimated as the total population size, minus the 121 population of women of childbearing age. Variants were classified as non-variant of concern, 122 N501Y+ variant (including the Alpha, Beta and Gamma variants), or Delta variant, as described We explored temporal trends in case incidence overall, in women aged 10-49, and in 136 pregnant women, graphically and through calculation of standardized morbidity ratios (SMR) as 137 described in (27). Briefly, SMR were estimated as incidence in pregnant women, or non-138 pregnant women of child-bearing age, divided by incidence in the population overall. We 139 calculated SMR for the entire study period, and by week. Confidence intervals for proportions 140 were estimated based on standard errors for log-SMR as in (27). 141

We used multivariable conditional logistic regression models to estimate the risk of 142 severe illness among our matched cohort while adjusting for age (treated as a four-level ordinal 143 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. ; https://doi.org/10.1101/2022.03.04.22271915 doi: medRxiv preprint variable), comorbidity, healthcare worker status, vaccination status, and infecting variant, all of 144 which were selected a priori. Severe illness was defined as hospitalization or intensive care unit 145 (ICU) admission. We were not able to include death as an outcome because fewer than five 146 pregnant individuals had died of SARS-CoV-2 in Ontario at the time of analysis. Due to small 147 numbers of adverse outcomes in individuals vaccinated with three doses, we treated vaccination 148 as an ordinal variable with three levels (i.e., unvaccinated, one dose, and two or more doses). 149

As some pregnant individuals infected with SARS-CoV-2 might be hospitalized for 150 monitoring, we performed an additional restriction analysis, in which risk of ICU was evaluated 151 among pregnant and non-pregnant women admitted to hospital. We hypothesized that if 152 pregnant individuals were admitted for precautionary reasons, they would be less likely to be 153 admitted to ICU than non-pregnant controls, and if admission was due to severity of illness, 154 pregnant individuals should be as or more likely than non-pregnant controls to be admitted to 155 ICU. Due to lack of within-stratum variance in healthcare worker status and infecting variant 156 among those admitted to hospital, we adjusted only for age, comorbidity, and vaccination in 157 analyses restricted to hospitalized individuals. 158

We performed a series of exploratory restriction analyses within each stratum of 159 comorbidity status, age group, vaccination status, or infecting variant variables to evaluate 160 modification of the observed effects by these covariates in pregnant individuals and non-161 pregnant controls. As conditional logistic regression models failed to converge for some of these 162 models, we used logistic regression models with time modeled as a cubic term. Heterogeneity in 163 adjusted odds ratios for hospitalization and ICU admission was evaluated using meta-analytic 164 techniques (i.e., graphically using forest plots, and statistically using the meta-analytic Q 165 statistic). Our study was conducted in accordance with the STROBE guidelines for 166 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022.

Our final cohort consisted of 2,252 pregnant women and 11,257 non-pregnant controls, 173 with 5 controls for all but 3 cases (which had 4 matched controls each), with test dates between 174

March 16, 2020, and January 4, 2022. While the temporal pattern of infection risk in pregnant 175 individuals and non-pregnant women of child-bearing age mirrored risk in the population as a 176 whole over time, risk was elevated in non-pregnant women of childbearing age (SMR 1.28) and 177 decreased in pregnant women (SMR 0.43) (Figure 2) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. increase in hospitalization and ICU risk associated with pregnancy is due to varying propensity 213 to receive vaccination over time, or by temporal changes in circulating variants of concern. 214 Furthermore, we did not see a diminished risk of intensive care admission in hospitalized 215 pregnant women when they were compared to other hospitalized women, suggesting that 216 pregnant women were likely to have been admitted to hospital for severity of respiratory illness 217 rather than simply for monitoring. 218

The excess risk associated with pregnancy was less pronounced when analyses were 219 restricted to pregnant and non-pregnant women who had comorbidities, again suggesting that in 220 otherwise healthy women, pregnancy itself is a factor that increases illness severity, while in 221 women with comorbidities it becomes one of several factors that augments risk. The physiology 222 of increased severity of respiratory virus infection in pregnancy is complex, and not fully 223 understood in the context of SARS-CoV-2. While pregnant women have increased cardiac 224 demand, diminished pulmonary reserve, and physiological impairment of the immune response 225 (which serves to prevent rejection of the developing fetus), and these changes have been linked 226 to worse outcome with pulmonary infection (5, 29) , COVID-19 is not simply an infection of the 227 respiratory system. Numerous vascular and hematological abnormalities occur following SARS-228 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. ; https://doi.org/10.1101/2022.03.04.22271915 doi: medRxiv preprint CoV-2 infection, and reports of elevated risk of stillbirth in infected individuals (12) , and 229 pathological changes reported in the placenta (30) , may suggest that some of the excess 230 morbidity we describe here is related to vascular and hematological disease rather than 231 respiratory disease. 232

While our primary aim in this study was to evaluate the impact of pregnancy on risk of 233 severe illness with SARS-CoV-2, vaccination, including partial vaccination, was associated with 234 a marked reduction in hospital admission risk and ICU admission in multivariable analyses, 235 notwithstanding the fact that in this case-only analysis, all vaccinated women had, by definition, 236 experienced breakthrough infections. Again, given the safety of these vaccines in pregnancy (8), 237 and the markedly elevated risk of severe illness in pregnancy, risk calculus strongly favours 238 vaccination for pregnant women. 239

Like any observational study, ours is subject to several limitations. First, the inability to 240 perform linkage of mothers and infants using available data prevents us from evaluating the 241 question of whether maternal vaccination is likely to reduce risk associated with SARS-CoV-2 242 infection in live-born infants, though anti-spike antibody is present in infants born to vaccinated 243 mothers, and is present at higher titres, and persists longer, than antibody in infants born to 244 mothers with SARS-CoV-2 infection (31) . The recent emergence of the Omicron variant makes 245 us unable to explore the relative virulence of this variant in pregnancy in the current paper (23) . 246

Our estimates may also be subject to residual confounding by incompletely ascertained factors, 247 including presence of underlying medical conditions. However, the very large effect size 248 associated with pregnancy means that the magnitude of effect of putative confounding factors 249 needed to explain away these associations would be implausibly large (32) . 250

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. ; https://doi.org/10.1101/2022.03.04.22271915 doi: medRxiv preprint

In summary, we identify a large increase in risk of hospitalization and ICU admission in 251 pregnant women infected with SARS-CoV-2 virus, relative to female controls of child-bearing 252 age. This effect was not explained by comorbidity or vaccination status, and indeed, the relative 253 increase in risk with pregnancy was greater when we restricted our analyses to women without 254 medical comorbidities. Vaccination markedly reduced hospitalization and ICU admission risk in 255 all women, pregnant and non-pregnant, in this study, and should be strongly encouraged in 256 pregnancy. 257 258 Acknowledgements 259

The authors with to thank the staff at Public Health Ontario and Ontario's public health units for 260 collecting, sequencing, analyzing, and providing access to the data used for this analysis. 261 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Absolute numbers not shown for deaths, or specific comorbidities (liver disease and COPD) due to concern with identifiability with small cell sizes (N < 5). Differences between pregnant and non-pregnant women were non-significant (P > 0.50) for all of these outcomes and characteristics. Proportions compared using chi-squared tests. *Adjusted for vaccination status, age, healthcare worker status, variants of concern, and time cubed.

NOTE: CI, confidence interval; aOR, adjusted odds ratio.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 7, 2022. ; https://doi.org/10.1101/2022.03.04.22271915 doi: medRxiv preprint

Emerging infections and pregnancy

Immunological relationship between the mother and the fetus

Immune responses during gestational malaria: a review of the current knowledge and future trend of research

Host immune status and response to hepatitis E virus infection

Acute respiratory failure and mechanical ventilation in pregnant patient: A narrative review of literature

Ventilator management in critical illness

Critical Care Obstetrics. 5 ed

Fetal effects of drugs commonly used in critical care

Systematic review of the safety, immunogenicity, and effectiveness of COVID-19 vaccines in pregnant and lactating individuals and their infants

Attitudes of pregnant women toward COVID-19 vaccines: a mixedmethods study

COVID-19 Vaccine Acceptance of Pregnant and Lactating Women (PLW) in Czechia: An Analytical Cross-Sectional Study

Risk for Stillbirth Among Women With and Without COVID-19 at Delivery Hospitalization -United States

Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Canada: Coronavirus Pandemic Country Profile. Available via the Internet at

COVID-19 United States Cases by County

Excess All-Cause

Mortality During the COVID-19 Epidemic in Canada

Canadian Surveillance of COVID-19 in Pregnancy (CANCOVID-Preg): A Rapidly Coordinated National Response Using Established Regional Infrastructures

Canadian surveillance of COVID-19 in pregnancy: Epidemiology, maternal and infant outcomes

Last accessed

Population estimates

Ontario Agency for Health Protection and Promotion (Public Health Ontario)

Available via the Internet at publichealthontario.ca/-/media/documents/ncov/epi/covid-19-vaccine-uptake-ontario-episummary

Progressive Increase in Virulence of Novel SARS-CoV-2

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2

Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario

Influenza infection and vaccination in pregnant women

Placental Pathology Findings during and after SARS-CoV-2 Infection: Features of Villitis and Malperfusion

Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection

Sensitivity Analysis in Observational Research: Introducing